Abstract:Few new therapeutics exist to target airway inflammation in mild-to-moderate asthma. Alveolar macrophages regulate airway inflammation by producing proresolving eicosanoids. We hypothesized that stimulation of the purinergic receptor P2X7 in macrophages from individuals with asthma produces eicosanoids associated with airway inflammation and resolution, and that these responses are predicted, in part, by P2X7 pore function. Study subjects were recruited in an Institutional Review Board (IRB)-approved study. Alveolar macrophages were recovered from bronchoalveolar lavage fluid following bronchoscopy. Purinergic receptor classification was performed using flow cytometry and fluorescent cell assay. Macrophages were stimulated in vitro and eicosanoids were measured via ELISA or enzyme immunoassay (EIA) in the presence and absence of P2X7-specific agonist [2'(3')-O-(4-Benzoylbenzoyl)adenosine-5'-triphosphate tri(triethylammonium) salt (Bz-ATP)] and antagonist (AZD9056). Functional P2X7 pore status was confirmed in a live cell assay using P2X7-specific agonists and antagonists. Alveolar macrophages produced increased quantities of the oxylipins lipoxin A4 (LXA4), resolvin D1 (RvD1), and 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE) following stimulation with Bz-ATP compared with vehicle controls, responses that were attenuated in the presence of the P2X7-selective antagonist, AZD9056. LXA4 and RvD1 production was greatest at 1 h, whereas 15(S)-HETE was maximally produced 24 h. Prostaglandin E-2 and resolvin E1 were minimally produced by P2X7 activation, indicating differential signaling pathways involved in eicosanoid production in alveolar macrophages derived from individuals with asthma. The early production of the proresolving eicosanoids, LXA4 and resolvin D1, is regulated by P2X7, whereas generation of the proinflammatory eicosanoid, 15(S)-HETE, is only partially regulated through P2X7 signaling and reaches maximal production after the peak in proresolving eicosanoids.NEW & NOTEWORTHY Alveolar macrophages obtained from individuals with asthma produce soluble lipid mediators in response to P2X7 purinergic receptor signaling. Proinflammatory mediators may contribute to asthma exacerbations but proresolving mediators may help with resolution of asthma loss of control. These specialized proresolving lipid mediators may serve as future potential therapeutics for asthma exacerbation resolution and recovery.

Purinergic P2X7 receptor regulates lung surfactant secretion in a paracrine manner.

Purinergic P2X7 Receptor: A Pivotal Role in Surfactant Regulation?

Mechanosensitive Channels TMEM63A and TMEM63B Mediate Lung Inflation-Induced Surfactant Secretion

Regulation of Lung Surfactant Secretion by Microrna-150

P2X7 Receptor Indirectly Regulates the JAM-A Protein Content via Modulation of GSK-3β

P2X7 signaling influences the production of pro-resolving and pro-inflammatory lipid mediators in alveolar macrophages derived from individuals with asthma

Vacuolar ATPase Regulates Surfactant Secretion in Rat Alveolar Type II Cells by Modulating Lamellar Body Calcium

P2X7 RECEPTOR PLAYS A CRUCIAL ROLE IN LPS‐MEDIATED ACUTE LUNG INJURY

Upregulation of Surfactant Synthesis Triggers ABCA1-mediated Basolateral Phospholipid Efflux.

Effect of nitric oxide on lung surfactant secretion.

Effect of P2X7 Receptor Knockout on AQP-5 Expression of Type I Alveolar Epithelial Cells

Purinergic regulation of pulmonary vascular tone

Prolonged Activation Of P2x7r Leads To Alveolar Epithelial Type I Cell Death By Suppressing Wnt/Beta-Catenin Pathway

Pore properties and pharmacological features of the P2X receptor channel in airway ciliated cells

Adsorption of surfactant to bronchial epithelium: possible role of receptor 'unmasking' in asthma.

[Modulation of Endothelin-1 on Pulmonary Surfactant Secretion].

Blocking P2Y2 purinergic receptor prevents the development of lipopolysaccharide-induced acute respiratory distress syndrome

Vacuolar Atpases: Insights into Lung Surfactant Secretion

Mir‐20a‐5p Regulates Pulmonary Surfactant Gene Expression in Alveolar Type II Cells

Purinergic signalling links mechanical breath profile and alveolar mechanics with the pro-inflammatory innate immune response causing ventilation-induced lung injury

Surfactant protein A regulates the expression of MIP-2 and inhibits NF-κB binding activity in tubular epithelial cells